论文部分内容阅读
目的探究常规化疗联合硼替佐米及沙利度胺对新发骨髓瘤患者伴肾功能衰竭的影响。方法将2013年6月—2015年8月收治的89例新发骨髓瘤伴肾功能衰竭患者随机分为对照组和观察组,对照组实施常规化疗治疗,观察组在常规化疗的前提下加用硼替佐米与沙利度胺治疗,比较两组肾功能改善效果与病情改善情况进行对比,计数资料采用χ~2检验,以P<0.05为差异有统计学意义。结果观察组肾功能改善总有效率78.95%高于对照组的53.12%,两组比较差异有统计学意义(χ~2=6.466,P<0.05);观察组总有效率80.70%高于对照组的53.12%,两组比较差异有统计学意义(χ~2=7.537,P<0.05)。结论新发骨髓瘤患者伴肾功能衰竭采用常规化疗与加用硼替佐米与沙利度胺的治疗效果显著,可使患者的肾功能明显改善,在临床上有较高的应用价值。
Objective To investigate the effect of conventional chemotherapy combined with bortezomib and thalidomide on patients with newly diagnosed myeloma with renal failure. Methods Eighty-nine patients with newly diagnosed myeloma and renal failure who were admitted to our hospital from June 2013 to August 2015 were randomly divided into control group and observation group. The control group was treated with conventional chemotherapy. The observation group was treated with conventional chemotherapy Bortezomib and thalidomide were compared. The improvement of renal function was compared with the improvement of disease. The count data were tested byχ ~ 2 test, and the difference was statistically significant at P <0.05. Results The total effective rate of improvement of renal function in observation group was 78.95%, which was significantly higher than that in control group (53.12%), the difference was statistically significant (χ ~ 2 = 6.466, P <0.05). The total effective rate in observation group was 80.70% Of 53.12%, the difference between the two groups was statistically significant (χ ~ 2 = 7.537, P <0.05). Conclusion The treatment of patients with newly diagnosed myeloma with renal failure by conventional chemotherapy plus bortezomib and thalidomide is significant, which can significantly improve the renal function in patients with advanced myeloma and has a high clinical value.